CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 233 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $288,649 | +9.3% | 24,692 | +25.7% | 0.00% | 0.0% |
Q2 2023 | $264,069 | -18.9% | 19,648 | 0.0% | 0.00% | -50.0% |
Q1 2023 | $325,764 | +15.1% | 19,648 | +29.1% | 0.00% | 0.0% |
Q4 2022 | $283,148 | +137.9% | 15,223 | +64.8% | 0.00% | +100.0% |
Q3 2022 | $119,000 | +83.1% | 9,240 | 0.0% | 0.00% | – |
Q2 2022 | $65,000 | -52.6% | 9,240 | -44.1% | 0.00% | -100.0% |
Q1 2022 | $137,000 | +144.6% | 16,535 | +99.8% | 0.00% | – |
Q4 2021 | $56,000 | +51.4% | 8,277 | +19.9% | 0.00% | – |
Q3 2021 | $37,000 | -7.5% | 6,904 | 0.0% | 0.00% | – |
Q2 2021 | $40,000 | +25.0% | 6,904 | 0.0% | 0.00% | – |
Q1 2021 | $32,000 | +39.1% | 6,904 | 0.0% | 0.00% | – |
Q4 2020 | $23,000 | +9.5% | 6,904 | 0.0% | 0.00% | – |
Q3 2020 | $21,000 | -34.4% | 6,904 | 0.0% | 0.00% | – |
Q2 2020 | $32,000 | +18.5% | 6,904 | 0.0% | 0.00% | – |
Q1 2020 | $27,000 | +3.8% | 6,904 | 0.0% | 0.00% | – |
Q4 2019 | $26,000 | -29.7% | 6,904 | 0.0% | 0.00% | – |
Q3 2019 | $37,000 | +54.2% | 6,904 | +9.4% | 0.00% | – |
Q2 2019 | $24,000 | – | 6,309 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANAKA CAPITAL MANAGEMENT INC | 252,199 | $749,000 | 2.35% |
MANGROVE PARTNERS IM, LLC | 3,031,965 | $9,005,000 | 1.14% |
ARMISTICE CAPITAL, LLC | 10,000,000 | $29,700,000 | 1.08% |
GABLES CAPITAL MANAGEMENT INC. | 432,864 | $1,286,000 | 0.83% |
Worth Venture Partners, LLC | 268,682 | $798,000 | 0.66% |
XTX MARKETS LLC | 18,749 | $56,000 | 0.27% |
Capital Impact Advisors, LLC | 203,133 | $603,000 | 0.18% |
Wealthspire Advisors, LLC | 337,770 | $1,003,000 | 0.06% |
ROYCE & ASSOCIATES LP | 1,784,890 | $5,301,000 | 0.06% |
XML Financial, LLC | 40,000 | $119,000 | 0.04% |